Literature DB >> 6604840

Murine lupus nephritis. Effects of glucocorticoid on circulating and tissue-bound immunoreactants.

T Cavallo, K Graves, N A Granholm.   

Abstract

We investigated the effects of methylprednisolone on immunoreactants of plasma and kidney to determine factors that might be relevant to the arrest of murine lupus nephritis. At the onset of nephritis, at about 5 months of age, the mice were divided in two groups and received either methylprednisolone or saline injections for 12 weeks. Before and after therapy (or saline injections), we determined the concentrations of plasma IgG, complement (C3), anti-DNA antibodies, Clq-reactive materials, creatinine, and urea nitrogen; in the kidneys, we assessed the relative distribution of IgG, IgM, and C3 in glomeruli, and we determined the concentration of IgG and anti-DNA activity of the eluted proteins. Our results indicated that methylprednisolone administered at the onset of nephritis preserved glomerular structure and function by decreasing the amount of tissue-bound immunoreactants and by inducing a preferential localization of immunoreactants in mesangia. Of the immunoreactants studied in plasma, a decreased concentration of IgG, but not the concentrations of anti-DNA antibodies, C3, and Clq-reactive materials, was associated with the arrest of nephritis. The anti-DNA activity in the renal eluates was very low and comparable in treated and untreated mice. Immune complex systems other than, or in addition to, DNA-anti-DNA likely play a role in the pathogenesis of murine lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604840

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

Review 1.  Autoimmunity and glomerulonephritis.

Authors:  R Saxena; C Johansson; P Bygren; J Wieslander
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

Review 2.  The role of anti-DNA antibodies in lupus nephritis.

Authors:  M Waer
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

3.  Effect of chlorpromazine on the development of experimental glomerulonephritis and Arthus reaction.

Authors:  G Camussi; G Salvidio; N Niesen; J Brentjens; G Andres
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

4.  Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis.

Authors:  H C Gunn; B Ryffel
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

5.  Nephritogenicity of the lprcg gene on the MRL background.

Authors:  M Kimura; Y Ogata; K Shimada; T Wakabayashi; H Onoda; T Katagiri; A Matsuzawa
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

6.  Perforin mRNA expression in the inflamed tissues of NZB/W F1 lupus mice decreases with methylprednisolone treatment.

Authors:  T Nakamura; I Ebihara; Y Tomino; K Okumura; H Koide
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

7.  Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders.

Authors:  R Saxena; G Sturfelt; O Nived; J Wieslander
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

8.  Suppression of autoimmune disease in NZB/W F1 mice by treatment with the novel immunomodulator BTS 63155.

Authors:  P Appleby; G Telford; G B Naylor
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

Review 9.  Modelling clinical systemic lupus erythematosus: similarities, differences and success stories.

Authors:  Teja Celhar; Anna-Marie Fairhurst
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.